2023 ASN Kidney Week Abstract: DNlite IVD103 with CKD and Coronary Artery Disease in Diabetic Nephropathy
A study supported by Bio Preventive Medicine Corp., “Association of Urinary DNlite IVD-103 with CKD and Coronary Artery Disease in Diabetic Nephropathy” by Dr. Varun Kumar Bandi, Harsha Nnss
Saudi FDA Approval Announcement
Bio Preventive Medicine Corp. announced on December 8, 2023 that its IVD products, DNlite-DKD uPTM-FetA ELISA Kit (aka DNlite-IVD103-DKD) and DNlite-KT uPTM-FetA ELISA Kit (aka DNlite-IVD103-KT)
Taiwan FDA Approval Announcement
Bio Preventive Medicine Corp. announced on January 3, 2024 that its IVD product, DNlite-DKD uPTM-FetA ELISA Kit (aka DNlite-IVD103-DKD) has received marketing approval from Taiwan FDA.
U.A.E. Approval Announcement
Bio Preventive Medicine Corp. announced that its IVD product, DNlite-DKD uPTM-FetA ELISA kit (aka DNlite-IVD103) has received the classification letter from Ministry of Health and PreventionMoHAP of United Arab Emirates.
DNlite-IVD103 received Market Authorization License from Ministry of Health of Vietnam
Bio Preventive Medicine Corp. (BPM) announced that its IVD product, DNlite-DKD uPTM-FetA ELISA kit (aka DNlite-DKD) has received Market Authorization License from Vietnamese Ministry of Health.
DNlite-IVD103 received registration license from Indonesian Ministry of Health
Bio Preventive Medicine Corp. (BPM) announced that its IVD product, DNlite-DKD uPTM-FetA ELISA kit (aka DNlite-IVD103) has received registration license from Indonesian Ministry of Health. It will be the first innovative biomarker IVD product entering Indonesia market from Taiwan.
BPM signed an License MOU with Boditech Med Inc., a Korean company, to officially enter the POCT market with DNlite-IVD103
Bio Preventive Medicine Corp. (hereinafter referred to as “BPM”, TW stock code: 6810) announced that it has completed the signing of a License MOU with South Korea’s Boditech Med Inc. (Boditech Med)